Schilke Tobin

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
12
Insider Sells Sum
$2.07M

Insider Activity of Schilke Tobin

According to the SEC Form 4 filings, Schilke Tobin, being in a position of

  1. CFO at Revance Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 9361 share for $47,204,
    over all time since 2023-01-09, has bought 0 shares, and sold 71686 shares for $2.07M.

The largest sale of all time was on 2023-05-15 and amounted to 21401 share of Revance Therapeutics, Inc. for $739,338.

Biography of Schilke Tobin

No biography is available at this moment.

2024-03-18SaleRevance Therapeutics, Inc.
RVNC
CFO
9,361
0.0092%
$5.04$47,204-20.04%
2023-07-03SaleRevance Therapeutics, Inc.
RVNC
CFO
1,701
0.0021%
$25.04$42,593-72.17%
2023-06-02SaleRevance Therapeutics, Inc.
RVNC
CFO
500
0.0006%
$31.00$15,500-75.42%
2023-06-01SaleRevance Therapeutics, Inc.
RVNC
CFO
2,701
0.0033%
$30.57$82,570-74.75%
2023-05-15SaleRevance Therapeutics, Inc.
RVNC
CFO
21,401
0.0269%
$34.55$739,338-75.34%
2023-05-01SaleRevance Therapeutics, Inc.
RVNC
CFO
3,201
0.0039%
$31.70$101,472-73.21%
2023-04-03SaleRevance Therapeutics, Inc.
RVNC
CFO
3,201
0.0038%
$32.15$102,912-68.27%
2023-03-09SaleRevance Therapeutics, Inc.
RVNC
CFO
18,517
0.0233%
$31.59$584,884-45.58%
2023-03-01SaleRevance Therapeutics, Inc.
RVNC
CFO
3,201
0.0041%
$33.50$107,234-45.58%
2023-02-01SaleRevance Therapeutics, Inc.
RVNC
CFO
3,201
0.004%
$34.60$110,755-35.59%
2023-01-20SaleRevance Therapeutics, Inc.
RVNC
CFO
1,000
0.0012%
$31.00$31,000-28.2%
2023-01-09SaleRevance Therapeutics, Inc.
RVNC
CFO
3,701
0.0041%
$27.16$100,525-21.63%
Company
About Prismo.proPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.